Figure 5: Pannexin channel inhibitors, carbenoxolone (CBX) and trovafloxacin (Trovan), prevent or reverse mechanical hypersensitivity when administered systemically.
From: Hematopoietic pannexin 1 function is critical for neuropathic pain
(A) Diagram depicting two dosing schemes. (B,D) The effect of early, daily IP CBX (B, 30 mg/kg in saline, n = 10–11 per condition) or Trovan (D, 30 mg/kg in DMSO, n = 10 per condition) and the respective vehicles. At day 7, pain development was significantly blunted by drug treatment, relative to vehicle; after the drug was withdrawn, full hypersensitivity was observed at day 28. (*p < 0.05 by two-way RM-ANOVA followed by Sidak’s multiple comparison test). (C,E) Changes in hypersensitivity after daily IP injections of CBX or saline (C, n = 12–13), and after Trovan or DMSO beginning at POD7 (E, n = 12–13). Mechanical sensitivity was partially relieved by both drugs, comparing pre- and post-treatment values (dotted lines: 95% CI for pre-operation baselines; *p < 0.05 by two-way RM-ANOVA followed by Sidak’s multiple comparison test).
